Provepharm

14 articles about Provepharm

• Calyptus Pharmaceuticals Announces Partnership with Provepharm to Accelerate Development of an Acute Care Injectable Product

  8/22/2022

  Calyptus Pharmaceuticals, Inc., ("Calyptus") announced that it entered into an agreement with Provepharm SAS ("Provepharm"), to accelerate the development, marketing and distribution of a complex injectable product used in acute care settings.

• Provepharm announces that it has received FDA approval for BLUDIGOTM (Indigotindisulfonate Sodium, USP) Injection.

  7/12/2022

  Provepharm, a French company with operations in the United States of America, specializing in the development of pharmaceutical applications, today announced that it has received FDA New Drug Approval for the marketing of its injectable BLUDIGO™ (Indigotindisulfonate Sodium) Injection. 

• American Regent Launches a New Vial Presentation

  6/30/2022

  American Regent, Inc. and Provepharm Life Solutions are pleased to announce the availability of ProvayBlue® Injection, USP in a 10 mL single-dose vial.

• Provepharm Life Solutions invests €9M in its new pilot production unit

  9/25/2019

  Company inaugurates its new production unit for active pharmaceutical ingredients, the cornerstone of Provepharm’s development

• Provepharm Life Solutions receives €42M

  5/9/2019

  New funding will enable pharmaceutical group to accelerate program of international growth through acquisitions

• PROVEPHARM LIFE SOLUTIONS WINS THE 2018 PRIX GALIEN-MEDSTARTUP AWARD

  10/30/2018

  Provepharm Life Solutions, a French independent pharmaceutical and life sciences group which revitalizes known molecules, announces today it has won the 2018 Prix Galien-Medstartup Award.

• Provepharm’s Proveblue Methylene Blue Drug Substance Achieves Full Compliance With The Latest US And European Pharmacopoeial Standards

  11/21/2016

• Provepharm Receives FDA Approval For Marketing Of Provayblue (Methylene Blue) Injection

  5/11/2016

• Provepharm Launches Provedye®, Its First Medical Device, In Europe

  1/27/2015

• Provepharm Announces That Its Partner In Japan, Daiichi Sankyo, Inc. Has Filed An NDA For The Marketing Of The Methylene Blue Injection Medicinal Product In Japan, Made Out Of Proveblue® Methylene Blue Active Substance

  3/19/2014

• Provence Technologies And Provepharm Invest EUR 4 Million In Their New Head Office

  1/27/2014

• Provepharm Continues Its International Expansion by Signing Three New Distribution Agreements in Europe

  7/5/2012

• Provepharm Obtains European Marketing Authorization for its Methylthioninium Chloride Proveblue

  5/24/2011

• Provepharm Receives Favorable European Medicines Evaluation Agency Review of its Methylthioninium Chloride Proveblue

  3/11/2011